OnQuality Pharmaceuticals to Have Two Abstracts Published in the 2022 ASCO Annual Meeting Proceedings

– Preclinical data demonstrating OQL051, a gut-restricted CDK4/6 inhibitor, as a potential prophylactic treatment for chemotherapy-induced diarrhea – Survey of academic and community oncologists studying the prevention and treatment patterns of papulopustular, acneiform skin toxicity…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.